AMGN · 10-Q · 2026Q3 · Full report
Trade Policy and Tariffs
AMGEN INC · 2026-11-04 · Importance 40 · Surprise 42 · In source text
Amgen reports that the U.S. Administration issued a proclamation in April 2026 imposing Section 232 tariffs on certain patented pharmaceuticals and associated active pharmaceutical ingredients. The company says it received relief from Section 232 tariffs for approximately three years from December 2025, in recognition of its U.S. manufacturing capital investments. It cautions that tariffs and other trade-protection measures may adversely affect its business and results of operations; no dollar impact is provided.
Key facts
- In April 2026, the Administration issued a proclamation imposing Section 232 tariffs on certain patented pharmaceuticals and associated active pharmaceutical ingredients. source
- In December 2025, Amgen received relief from Section 232 tariffs for approximately the next three years, in recognition of its U.S. manufacturing capital investments. source
- Amgen said tariffs and trade protection measures may adversely affect its business and results of operations. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | positive | committed | — | In December 2025, Amgen received relief from Section 232 tariffs for approximately the next three years, in recognition of its U.S.… |